Incidence of ceftriaxone-associated gallbladder pseudolithiasis

Acta Paediatrica, International Journal of Paediatrics

Volumn 88, Issue 12, 1999, Pages 1352-1355

  Papadopoulou, F ^a,b   Efremidis, S ^a   Karyda, S ^a   Badouraki, M ^a   Karatza, E ^a   Panteliadis, C ^a   Malaka, K ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

Author keywords

Bile sludge; Ceftriaxone; Gallbladder calculi; Ultrasound in infants and children

Indexed keywords

CEFTRIAXONE;

ADOLESCENT; ARTICLE; CHILD; CHOLELITHIASIS; CLINICAL ARTICLE; DRUG MEGADOSE; ECHOGRAPHY; FEMALE; HUMAN; INFANT; MALE; NEWBORN; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SLUDGE; STONE FORMATION;

EID: 0033390263     PISSN: 08035253     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.1999.tb01050.x     Document Type: Article

References (13)

1. 1. Neu HC, Meropold NJ, Fu KP. Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase stable cephalosporin. Antimicrob Agents Chemother 1981; 19: 414-23
2. 2. Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs 1984; 27: 469-527
3. 3. McNamara BY, Stoeckel K, Siegler WH. Pharmacokinetics of ceftriaxone following intravenous administration of a 3-g dose. Eur J Clin Pharmacol 1982; 22: 71-5
4. 4. Schaad UB, Wedgwood-Krucko J, Tschaeppeler H. Reversible ceftriaxone-associated biliary pseudolithiasis in children. Lancet 1988; 2: 1411-3
5. 5. Pigrau C, Pahissa A, Gropper S, Sureda D, Martinez-Vazquez JM. Ceftriaxone-associated pseudolithiasis in adults. Lancet 1989; 2: 165
6. 6. Heim-Duthoy KL, Peterson PK, Enthoven D, Matzke CR, Pollock R, Caperton EM. Apparent biliary pseudolithiasis during ceftriaxone therapy. Antimicrob Agents Chemother 1990; 34: 1146-9
7. 7. Zinberg J, Chernaik R, Coman E, Rosenblatt R, Brandt LJ. Reversible symptomatic biliary obstruction associated with ceftriaxone pseudolithiasis. Am J Gastroenterol 1991; 86: 1251-4
8. 8. Robertson FM, Crombleholme TM, Barlow SE, Vehave M, Brown D. Ceftriaxone choledocholithiasis. Pediatrics 1996; 98: 133-5
9. 9. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge. Identification of calcium-ceftriaxone salt as a major component of gallbladder precipitate. Gastroenterology 1991; 100: 1665-70
10. 10. Xia Y, Lambert KJ, Schteingart CD, Gu JJ, Hoffman AF. Concentrative biliary secretion of ceftriaxone. Inhibition of lipid secretion and precipitation of calcium ceftriaxone in bile. Gastroenterology 1990; 99; 454-65
11. 11. Brogard JM, Buckle JF, Jehl F, Arnaud JP, Paris-Bockel D, Montei H. High biliary elimination of ceftriaxone in man. Int J Clin Pharmacol Ther Toxicol 1988; 26: 167-72
12. 12. Kim YS, Lee SP, Kastell MF. Gallbladder sludge: lessons from ceftriaxone. J Gastroenterol Hepatol 1992; 7: 618-21
13. 13. Blais C, Duperval R. Biliary pseudolithiasis in a child associated with 2 days of ceftriaxone therapy. Pediatr Radiol 1994; 24: 218-9